Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Results of the VITAL trial show Cerebrotech's non-invasive portable VIPS technology can distinguish patients with large-vessel occlusion strokes and large hemorrhagic strokes versus less-urgent strokes. The company hopes emergency responders will use its unique diagnostic visor to shorten the time it takes for patients suffering major strokes to get to a hospital that has the facilities to treat the stroke effectively.
French start-up LimFlow is developing a percutaneous deep vein arterialization system, designed for installing a stent-graft that shunts blood from a diseased tibial artery into a tibial vein to revascularize the foot of a patient with severe peripheral artery disease.
Israeli company Rapid Medical has developed two controllable neurovascular interventional devices for stroke treatment: the Comaneci mesh device for aneurysm treatment, and the Tigertriever stent retriever for treating ischemic stroke.
MIT spin-off Podimetrics has developed a wireless SmartMat and a monitoring service that notifies patients and clinicians of an elevated risk that a diabetic foot ulcer is forming. The company hopes that new clinical trial data will prove compelling to physicians' treating this common and challenging complication of diabetes.
Israeli start-up Hemonitor Medical is hoping to make waves with a new hemodynamic monitor that uses an ultrasound patch technology to continuously monitor blood flow in ICU patients or patients in surgery. The company is the first start-up to be taken in by MindUP, Israel's first digital health incubator and a joint partnership between Medtronic, IBM, Pitango Venture Capital, Rambam Hospital and the Impact First investment fund.
US firm 4C Medical Technologies is developing a unique solution to mitral regurgitation that sits outside the valve and takes advantage of the native valve's remaining function while preventing mitral regurgitation. The Minnesota-based start-up is currently funded by angel investors and "friends and family," but expects to raise a $15m Series B round in early 2018.
Restoring the eyes' ability to accommodate and seamlessly focus on near and far objects continues to be the holy grail in ophthalmology. Accommodating intraocular lenses offer one approach to tackle presbyopia and allow patients the possibility of eschewing reading glasses. LensGen is one company going down that road and it successfully raised $21m in series A financing – with major optical lens maker Hoya among its backers – in April to advance its fluid-based accommodating IOL, Juvene.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.